China
2021.02.28 12:36 GMT+8

COVID-19 vaccine by Sinopharm's Wuhan institute becomes third to enter market in China

Updated 2021.02.28 12:36 GMT+8
CGTN

An inactivated COVID-19 vaccine developed by Sinopharm's Wuhan institute became the third vaccine to enter the market in China on Sunday, Hubei Daily reported.

The institute has a production capacity of 100 million doses per year, the report said.

Copyright © 

RELATED STORIES